China Universal Asset Management Co., Ltd. Affimed N.V. Transaction History

China Universal Asset Management Co., Ltd.

$1.03 Billion
Q4 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$0.46 - $0.65 $862 - $1,219	1,876 Added 95.86%	3,833 $1,000
Q3 2023 Oct 30, 2023	BUY	$0.46 - $0.65 $862 - $1,219	1,876 Added 95.86%	3,833 $2,000
Q2 2023 May 21, 2024	SELL	$0.57 - $1.08 $37 - $71	-66 Reduced 3.26%	1,957 $1,000
Q2 2023 Jul 27, 2023	SELL	$0.57 - $1.08 $37 - $71	-66 Reduced 3.26%	1,957 $1,000
Q1 2023 May 21, 2024	BUY	$0.66 - $1.29 $333 - $652	506 Added 33.36%	2,023 $1,000
Q1 2023 Apr 27, 2023	BUY	$0.66 - $1.29 $333 - $652	506 Added 33.36%	2,023 $2,000
Q4 2022 May 21, 2024	BUY	$1.1 - $2.45 $1,668 - $3,716	1,517 New	1,517 $1,000
Q4 2022 Jan 31, 2023	BUY	$1.1 - $2.45 $130 - $291	119 Added 8.51%	1,517 $2,000
Q3 2022 Oct 21, 2022	BUY	$1.96 - $3.32 $2,740 - $4,641	1,398 New	1,398 $3,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $155M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account